Clinical Policy Title: Vitiligo dermatology treatment
|
|
- Ethelbert Wade
- 5 years ago
- Views:
Transcription
1 Clinical Policy Title: Vitiligo dermatology treatment Clinical Policy Number: Effective Date: June 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: April 10, 2018 Next Review Date: April 2019 Policy contains: Vitiligo. Related policies: CP# Psoriasis dermatology treatment ABOUT THIS POLICY: AmeriHealth Caritas has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by AmeriHealth Caritas when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas will update its clinical policies as necessary. AmeriHealth Caritas clinical policies are not guarantees of payment. Coverage policy AmeriHealth Caritas considers vitiligo to be a remediable medical condition, and the use of treatments specified in this policy to be clinically proven and, therefore, medically necessary when the following criteria are met (Vakharia 2018, Mehraban 2014, Zhang 2010, Wang 2009, Gawkrodger 2008): Diagnosis of vitiligo is made by a primary care or specialty physician knowledgable in the diagnosis (i.e., clinical evaluation, skin biopsy) and treatment of these conditions. Treatment administered is an established method of care for vitiligo: Excimer laser (e.g., XTRAC, PhotoMedex, Radnor, Pennsylvania; EX-308, Ra Medical Systems Inc., Carlsbad, California). Narrow-band ultraviolet B (UVB). Topical and oral psoralen photochemotherapy (PUVA). Topical tacrolimus. Topical and systemic corticosteroids. 1
2 Limitations: All other treatments for vitiligo are considered to be investigational and, therefore, not medically necessary. Alternative covered services: Primary care and specialty physician (including surgical) evaluation and management. Background Vitiligo is an acquired depigmentary disorder characterized by white areas on the skin due to the loss of functional melanocytes. Excimer laser, in which excimer is a terminological reference of excited dimer, composed of a noble gas and halide (e.g., xenon and chloride) that repel each other, is a promising therapeutic choice though laser therapy in general is often compromised by complete or partial response. The advantages of monochromatic 308 nm excimer laser over other phototherapies include lower ultraviolet (UV) dose exposure, shorter course of therapy, and precise definition of treatment area, which helps prevent compromise of the adjacent normal skin. Medium doses of the 308-nm excimer laser have proven effective in the treatment of limited vitiligo; however, the rate and speed of repigmentation is highly associated with the site and duration of disease as the face and neck (UV-sensitive areas) are the highly respondent areas, along with an earlier resolution of the lesions, while the joints and extremities (UV-resistant areas) exhibit the slightest response to therapy. Topical and oral corticosteroids are among several therapeutic agents that have efficacy in this disorder. Very potent topical steroids are widely used to treat vitiligo, but the evidence for their effectiveness is limited. Folliculitis is a common side effect of treatment with potent topical steroids. Long-term daily treatment with oral corticosteroids, in most patients, requires continued treatment to maintain response and benefit is usually insufficient to justify the risks. Photochemotherapy with psoralen plus ultraviolet A (UVA) has demonstrated therapeutic responses but the relapse rate following treatment is high, and continued treatment is usually needed to maintain control, which may lead to an unacceptably high cumulative UVA dose. Tacrolimus also has shown variable response in the treatment of vitiligo. Searches AmeriHealth Caritas searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. 2
3 Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on February 12, Search terms were: vitiligo and psoriasis, vitiligo, and psoriasis. We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings Mehraban (2014) conducted a systematic review of the 308 nm xenon-chloride excimer laser in treatment of dermatologic disorders and reported verified efficacy in treating skin conditions such as vitiligo, psoriasis, atopic dermatitis, alopecia areata, allergic rhinitis, folliculitis, granuloma annulare, lichen planus, mycosis fungoides, palmoplantar pustulosis, pityriasis alba, CD30+ lympho proliferative disorder, leukoderma, prurigo nodularis, and localized scleroderma and genital lichen sclerosus. Wang (2014) treated 170 patients with the 308 nm excimer laser to assess its efficacy and safety for the treatment of vitiligo. The lesions of vitiligo were treated one to two times per week for 10 to 30 treatments. Efficacies were evaluated every seven days and three days after the treatments were completed. Patients were followed up for two months. The rates of "remarkably improved" and "cured" were percent and percent in faces, percent and percent in necks, percent and percent in trunks, percent and percent in limbs, and 0 percent and 0 percent in hands and feet. The areas of faces had a better response than those of necks, trunks, or limbs (P < 0.01), and the areas of trunks or limbs had better response than those of hands and feet (P < 0.01). The authors concluded that the 308 nm excimer laser is safe and effective in treating stable vitiligo and the efficacy varies in different lesion sites. The shorter the duration of disease, the more promising the treatment of vitiligo using a 308 nm excimer laser. Zhang (2010) studied 36 patients with 44 vitiligo patches who were treated using a 308 nm excimer laser twice a week. After 30 treatments: 27/44 patches (61.4 percent) achieved more than 75 percent repigmentation, 4/44 lesions (9.1 percent) showed 51 percent 75 percent repigmentation, 10/44 (22.7 percent) showed 26 percent 50 percent repigmentation and 3/44 (6.8 percent) showed 1 3
4 percent 25 percent repigmentation. Of the 44 patches of vitiligo, 20/27 (74.1 percent) lesions on the face and neck, 9/9 (100 percent) on the trunk and 2/8 (25.0 percent) on the extremities showed 50 percent repigmentation. The repigmentation ( 50 percent) in face and neck and trunk were much higher than that in the extremities (P < 0.05). The repigmentation 50 percent) in disease duration of two years and > two years were percent and 46.2 percent (P < 0.05). The average cumulative doses in the face and neck, trunk, and extremities were 7.92+/-5.26, 9.93+/-7.36, and /-8.15 J/cm 2. The doses in the face, neck, and trunk were much lower than those in the extremities (P < 0.05). Side effects were limited mainly to symptomatic erythema. Policy updates: A narrative review (Vakharia 2018) assessed the efficacy and safety of cellular grafting melanocytekeratinocyte transplantation in the treatment of vitiligo and other leukodermas. Numerous trials and case series/reports were cited to demonstrate the tolerability and efficacy of melanocyte-keratinocyte transplantation with repigmentation for patients with refractory, stable vitiligo. However, response rates were variable, likely influenced by vitiligo type and affected areas. Updated guidelines addressed practice in managing types of vitiligo, the process of diagnosis in primary and secondary care, and investigation of vitiligo by the British Association of Dermatologists (Gawkrodger 2008). Treatments considered include camouflage cosmetics and sunscreens, the use of topical potent or highly potent corticosteroids, of vitamin D analogues, and of topical calcineurin inhibitors, and depigmentation with p-(benzyloxy)phenol. The use of systemic treatment, e.g. corticosteroids, cyclosporine and other immunosuppressive agents was analyzed. Phototherapy was considered, including narrowband UVB, psoralen with UVA, and khellin with UVA or UVB, along with combinations of topical reparations and various forms of UV. Surgical treatments that were assessed include full-thickness and split skin grafting, mini (punch) grafts, Summary of clinical evidence: Citation Vakharia (2018) Efficacy and safety of noncultured melanocytekeratinocyte transplant procedure for vitiligo and other leukodermas: a critical analysis of the evidence. Mehraban (2014) Content, Methods, Recommendations A narrative review assessed the efficacy and safety of cellular grafting melanocyte-keratinocyte transplantation in the treatment of vitiligo and other leukodermas. Numerous trials and case series/reports were cited to demonstrate the tolerability and efficacy of melanocyte-keratinocyte transplantation with repigmentation for patients with refractory, stable vitiligo. However, response rates were variable, likely influenced by vitiligo type and affected areas. The 308-nm excimer laser in Systematic review on 308-nm excimer laser in dermatological disorders. 4
5 Citation Content, Methods, Recommendations dermatology Showed efficacy in treating vitiligo, psoriasis, atopic dermatitis, alopecia areata, allergic rhinitis, folliculitis, granuloma annulare, lichen planus, mycosis fungoides, palmoplantar pustulosis, pityriasis alba, CD30+ lympho proliferative disorder, leukoderma, prurigo nodularis, localized scleroderma, and genital lichen sclerosus. Zhang (2010) Clinical efficacy of a 308-nm excimer laser in the treatment of vitiligo Wang (2009) Efficacy and safety of 308-nm excimer laser for vitiligo Gawkrodger (2008) Randomized controlled trial (RCT) of 36 patients with 44 vitiligo patches who were treated using a 308 nm excimer laser twice a week. After 30 treatments: 27/44 patches (61.4%) achieved more than 75% repigmentation, 4/44 lesions (9.1%) showed 51% 75% repigmentation, 10/44 (22.7%) showed 26% 50% repigmentation, and 3/44 (6.8%) showed 1% 25% repigmentation. Of the 44 patches of vitiligo, 20/27 (74.1%) lesions on the face and neck, 9/9 (100%) on the trunk and 2/8 (25.0%) on the extremities showed 50% repigmentation. The repigmentation ( 50%) in face, neck, and trunk were much higher than that in the extremities (P < 0.05). The repigmentation ( 50%) in disease duration of two years and > two years were 100.0% and 46.2% (P < 0.05). The average cumulative doses in the face, neck, trunk, and extremities were 7.92+/-5.26, 9.93+/-7.36, and /-8.15 J/cm2. The doses in the face, neck, and trunk were much lower than those in the extremities (P < 0.05). Side effects were limited mainly to symptomatic erythema. Efficacies and safety of 308-nm excimer laser for vitiligo. Patients were followed up for two months. The rates of "remarkably improved" and "cured" were 67.97% and 32.03% in faces, 54.55% and 27.27% in necks, 63.26% and 26.53% in trunks, 38.84% and 15.70% in limbs, and 0% and 0% in hands and feet. The areas of faces had a better response than those of necks, trunks, or limbs (P < 0.01), and the areas of trunks or limbs had better response than those of hands and feet (P < 0.01). The authors concluded that the 308-nm excimer laser is safe and effective in treating stable vitiligo and the efficacy varies in different lesion sites. British Association of Dermatologists guideline for the diagnosis and management of vitiligoguidelines for the management of vitiligo and psoriasis. Guidelines updated from a previous version of 1992 addressed practice in managing types of vitiligo, the process of diagnosis in primary and secondary care, and investigation of vitiligo by the British Association of Dermatologists. Treatments considered include camouflage cosmetics and sunscreens, the use of topical potent or highly potent corticosteroids, of vitamin D analogues, and of topical calcineurin inhibitors, and depigmentation with p-(benzyloxy)phenol. The use of systemic treatment, e.g. corticosteroids, ciclosporin and other immunosuppressive agents was analyzed. 5
6 Citation Content, Methods, Recommendations Phototherapy was considered, including UVB, psoralen with UVA, and khellin with UVA or UVB, along with combinations of topical reparations and various forms of UV. Surgical treatments that were assessed include full-thickness and split skin grafting, mini (punch) grafts, autologous epidermal cell suspensions, and autologous skin equivalents. The effectiveness of cognitive therapy and psychological treatments was considered. Therapeutic algorithms using grades of recommendation and levels of evidence have been produced for children and for adults with vitiligo References Professional society guidelines/other: D.J. Gawkrodger, A.D. Ormerod, L. Shaw. British Association of Dermatologists guideline for the diagnosis and management of vitiligo. British Journal of Dermatology , pp Peer-reviewed references: Aghaei S. An uncontrolled, open label study of sulfasalazine in severe vitiligo and psoriasis. Indian J Dermatol Venereol Leprol 2008; 74: Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Vitiligo and psoriasis update: Part II: Treatment. J Am Acad Dermatol. 2010;62: Al-Mutairi N, Hadad AA. Efficacy of 308-nm xenon chloride excimer laser in pityriasis alba. Dermatol Surg. 2012;38: Al-Otaibi SR, Zadeh VB, Al-Abdulrazzaq AH, et al. Using a 308- nm excimer laser to treat vitiligo in Asians. Acta Dermatovenerol Alp Panonica Adriat. 2009;18:13 9. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of vitiligo and psoriasis. J Am Acad Dermatol 2009; 61: Cho S, Zheng Z, Park YK, Roh MR. The 308- nm excimer laser: a promising device for the treatment of childhood vitiligo. Photodermatol Photoimmunol Photomed. 2011;271:24 9. Feily A, Baktash D, Mohebbipour A, Feily A. Potential advantages of simvastatin as a novel anti-vitiligo arsenal. Eur Rev Med Pharmacol Sci. 2013;17: Feily A, Pazyar N. Why vitiligo is associated with fewer risk of skin cancer?: providing a molecular 6
7 mechanism. Arch Dermatol Res. 2011;303: Hubiche T, Leaute-Labreze C, Taieb A et al. Poor long-term outcome of severe vitiligo and psoriasis in children treated with high-dose pulse corticosteroid therapy. Br J Dermatol 2008;158: Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol. 2009;26(3): Ito T. Advances in the management of vitiligo and psoriasis, J Dermatol jan; 39(1):11-7. Le Duff F, Fontas E, Giacchero D, et al. 308-nm excimer lamp vs308- nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol. 2010;163(1): Mavilia L, Mori M, Rossi R, Campolmi P, Puglisi Guerra A, Lotti T. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol. 2008;143: Morita A, Weiss M, Maeda A. Recent developments in phototherapy: treatment methods and devices. Recent Pat Inflamm Allergy Drug Discov. 2008;2: Nisticò SP, Saraceno R, Schipani C, Costanzo A, Chimenti S. Different applications of monochromatic excimer light in skin diseases. Photomed Laser Surg. 2009;27: Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, e al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo--a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013;29(1): Strober BE, Menon K, McMichael A et al. Alefacept for severe vitiligo and psoriasis: a randomized, double-blind, placebo-controlled study.arch Dermatol 2009; 145: Vakharia PP, Lee DE, Khachemoune A. Efficacy and safety of noncultured melanocyte-keratinocyte transplant procedure for vitiligo and other leukodermas: a critical analysis of the evidence. Int J Dermatol Jan 10. doi: /ijd [Epub ahead of print] Review. PubMed PMID: Vine K, Meulener M, Shieh S, Silverberg NB. Vitiliginous lesions induced by amyl nitrite exposure. Cutis. 2013;91: Wang HW, Zuo YG, Jin HZ, Liu YH, Ma DL, Jiang GT. et al. Efficacy and safety of 308 nm excimer laser for vitiligo. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31:34 6. Welsh N, Guy A. The lived experience of vitiligo and psoriasis: a qualitative study. Body Image. 2009; 6:
8 Willemsen R, Haentjens P, Roseeuw D et al. Hypnosis in refractory vitiligo and psoriasis significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol 2010; 62: Zhang XY, He YL, Dong J, Xu JZ, Wang J. Clinical efficacy of a 308 nm excimer laser in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2010;26(3): CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): No LCDs identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comments Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B Photochemotherapy; psoralens and ultraviolet A (PUVA) Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm ICD-10 Code Description Comments L80.0 Vitiligo HCPCS Level II Code J0702 J1020 J1030 J1040 J1094 J1100 J1700 J1710 Description Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg Injection, methylprednisolone acetate, 20 mg Injection, methylprednisolone acetate, 40 mg Injection, methylprednisolone acetate, 80 mg Injection, dexamethasone acetate, 1 mg Injection, dexamethasone sodium phosphate, 1 mg Injection, hydrocortisone acetate, up to 25 mg Injection, hydrocortisone sodium phosphate, up to 50 mg Comments 8
9 HCPCS Level II Code J1720 J2650 J2920 J2930 J3301 J3302 J3303 J7509 J7510 J7512 J8540 Description Injection, hydrocortisone sodium succinate, up to 100 mg Injection, prednisolone acetate, up to 1 ml Injection, methylprednisolone sodium succinate, up to 40 mg Injection, methylprednisolone sodium succinate, up to 125 mg Injection, triamcinolone acetonide, NOS, 18 mg Injection, triamcinolone diacetate, per 5 mg Injection, triamcinolone hexacetinodie, per 5 mg Methylprednisolone, oral per 4 mg Prednisolone, oral, per 5 mg Prednisone, immediate reease or delayed release, oral, 1 mg Dexamethaone, oral 0.25 mg Comments 9
Clinical Policy Title: Vitiligo dermatology treatment
Clinical Policy Title: Vitiligo dermatology treatment Clinical Policy Number: 16.02.08 Effective Date: June 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: May 19, 2017 Next Review
More informationClinical Policy Title: Psoriasis dermatology treatment
Clinical Policy Title: Psoriasis dermatology treatment Clinical Policy Number: 16.02.06 Effective Date: October 1, 2016 Initial Review Date: September 17, 2016 Most Recent Review Date: September 21, 2017
More informationReview Article. 308nm Excimer Laser in Dermatology. Shadi Mehraban 1, Amir Feily 2
Review Article 308nm Excimer Laser in Dermatology Shadi Mehraban 1, Amir Feily 2 1Jahrom University of Medical Sciences, Jahrom, Iran 2Department of Dermatology, Jahrom University of Medical Sciences,
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationClinical Policy Title: Vitiligo and psoriasis
Clinical Policy Title: Vitiligo and psoriasis Clinical Policy Number: 16.02.06 Effective Date: October 1, 2017 Initial Review Date: September 17, 2016 Most Recent Review Date: September 17, 2016 Next Review
More informationSCIENTIFIC PAPER ABSTRACT
SCIENTIFIC PAPER ABSTRACT Vitiligo Treatment with Monochromatic Excimer Light and Tacrolimus: Results of an Open Randomized Controlled Study Nistico` S., Chiricozzi A., M.D., Rosita Saraceno R., Schipani
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service:
More informationPhotochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:
More informationClinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17
Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationClinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441
Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationA Vitiligo Update for Pharmacists: Current Practices and Future Advances
A Vitiligo Update for Pharmacists: Current Practices and Future Advances Dalal Hammoudi Halat, RPh, MSc, PhD Assistant Professor School of Pharmacy, Lebanese International University Disclosure Dalal Hammoudi
More informationLight Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.
Protocol Light Therapy for Psoriasis (20147) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 03/16, 03/17 Preauthorization is required. The following
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AA. See Alopecia areata. Acrofacial vitiligo presentation of, 135, 136 AD. See Atopic dermatitis. Adaptive immunity and vitiligo, 258
More informationClinical Policy Title: Alopecia areata
Clinical Policy Title: Alopecia areata Clinical Policy Number: 16.02.03 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next Review Date:
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationClinical Policy Title: Intralesional steroid injection for acne
Clinical Policy Title: Intralesional steroid injection for acne Clinical Policy Number: 16.02.07 Effective Date: June 1, 2017 Initial Review Date: April 19, 2017 Most Recent Review Date: May 19, 2017 Next
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationนพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด
Vitiligo Vitiligo Update Acquired pigmentary disorder Depigmented macules and patches นพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด Prevalence The prevalence of vitiligo is often said
More informationMedical Policy. MP Light Therapy for Psoriasis
Medical Policy MP 2.01.47 BCBSA Ref. Policy: 2.01.47 Last Review: 12/27/2017 Effective Date: 12/27/2017 Section: Medicine Related Policies 2.01.44 Dermatologic Applications of Photodynamic Therapy 2.01.86
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationBroad-band pulsed UVB and topical tacrolimus treatment for localized vitiligo -our experience.
ORIGINAL PAPERS 134 Broad-band pulsed UVB and topical tacrolimus treatment for localized vitiligo -our experience. Alexia Díaz Mathé 1, Virginia Mariana González 2, Verónica Llorca 1, Kamelia Losada 3,
More informationPhototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions
Last Review Date: October 12, 2018 Number: MG.MM.ME.27j Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationName of Policy: Phototherapy for the Treatment of Skin Disorders
Name of Policy: Phototherapy for the Treatment of Skin Disorders Policy #: 301 Latest Review Date: April 2014 Category: Medical/DME Policy Grade: B Background: As a general rule, benefits are payable under
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationClinical Policy Title: Phototherapy and photochemotherapy for skin conditions
Clinical Policy Title: Phototherapy and photochemotherapy for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date:
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationGLOSSARY of research terms
GLOSSARY of research terms SETTING PRIORITIES FOR VITILIGO RESEARCH - WORKSHOP Thursday 25 th March 2010 Types of studies Case Series: A study reporting on a consecutive collection of patients, treated
More informationClinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering)
Clinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering) Clinical Policy Number: 17.02.02 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent
More informationNarrow-band UVB PHOTOTHERAPY for Skin Diseases
Narrow-band UVB PHOTOTHERAPY for Skin Diseases By Dr. Manal Bosseila Cairo University, Egypt HISTORICAL ASPECT In 1978: Irradiation cabin with broad band UVB tubes was introduced for psoriasis & uremic
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Narrowband UVB Phototherapy in Combination
More informationPhototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions
Last Review Date: September 21, 2017 Number: MG.MM.ME.27iv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationTriamcinolone and vitiligo
P ford residence southampton, ny Triamcinolone and vitiligo Dermatologica. 1970;140(3):195-206. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Kandil E. PMID: 5414362;
More informationVitiligo. Vasanop Vachiramon, MD. Assistant professor Division of Dermatology, Ramathibodi Hospital
Vitiligo Vasanop Vachiramon, MD. Assistant professor Division of Dermatology, Ramathibodi Hospital Vitiligo Acquired pigmentary disorder Depigmented macules and patches Prevalence The worldwide prevalence
More informationLaser, Light Therapy, and Cryotherapy for Acne Vulgaris Non-Pharmacologic Treatment of Rosacea
2.01.47 Light Therapy for Psoriasis Section 2.0 Medicine Subsection Effective Date October 31, 2014 Original Policy Date June 13, 2001 Next Review Date October 2015 Description Plaque psoriasis, also called
More informationCorporate Medical Policy
Corporate Medical Policy Ultraviolet Light Therapy in the Home Setting(UVB) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultraviolet_light_therapy_in_the_home 3/1996 11/2017 11/2018
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ultraviolet Light Therapy for Skin Conditions Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ultraviolet Light Therapy for Skin Conditions Professional
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationName of Policy: Phototherapy for the Treatment of Skin Disorders
Name of Policy: Phototherapy for the Treatment of Skin Disorders Policy #: 301 Latest Review Date: December 2017 Category: Medical/DME Policy Grade: B Background: As a general rule, benefits are payable
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 11.03.05 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next
More informationLight Therapy for Psoriasis and Eczema
Light Therapy for Psoriasis and Eczema Policy Number: 2.01.47 Last Review: 5/2018 Origination: 5/2006 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationClinical Policy Title: Vacuum assisted closure in surgical wounds
Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Number: 17.03.00 Effective Date: September 1, 2015 Initial Review Date: June 16, 2013 Most Recent Review Date: August 17,
More informationClinical Policy Title: Dermabrasion and chemical peels
Clinical Policy Title: Dermabrasion and chemical peels Clinical Policy Number: 16.02.09 Effective Date: August 1, 2017 Initial Review Date: July 20, 2017 Most Recent Review Date: August 17, 2017 Next Review
More informationSummary. DOI /j x
PHOTOBIOLOGY DOI 10.1111/j.1365-2133.2005.06533.x Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis K. Köllner, M.B. Wimmershoff,
More informationClinical Policy Title: Frenectomy for ankyloglossia
Clinical Policy Title: Frenectomy for ankyloglossia Clinical Policy Number: 11.03.03 Effective Date: October 1, 2014 Initial Review Date: April 16, 2014 Most Recent Review Date: May 18, 2016 Next Review
More informationLight Therapy for Psoriasis. Description
Subject: Light Therapy for Psoriasis Page: 1 of 11 Last Review Status/Date: June 2015 Light Therapy for Psoriasis Description Light therapy for psoriasis includes both targeted phototherapy and photochemotherapy
More informationClinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity
Clinical Policy Title: Pharmocogenetic testing for warfarin (Coumadin ) sensitivity Clinical Policy Number: 02.01.13 Effective Date: September 1, 2013 Initial Review Date: May 15, 2013 Most Recent Review
More informationClinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions
Clinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: June 22, 2017 Next Review Date:
More informationA Retrospective Study of 231 Japanese Vitiligo Patients with Special Reference to Phototherapy
2014;22(1):13-18 CLINICAL ARTILCE A Retrospective Study of 231 Japanese Vitiligo Patients with Special Reference to Phototherapy Akiko Yoshida, Atsushi Takagi, Ayako Ikejima, Hiroshi Takenaka, Tatsuo Fukai,
More informationTHINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas
THINKING OUTSIDE THE BOX Ted Rosen, MD Baylor College of Medicine Houston, Texas RADICAL TOPICAL THERAPEUTIC PEARLS {SOMETIMES BASED ON BASICS} Hong Kong Jade Market 2014 ZINC! DISCLOSURE OF RELATIONSHIPS
More informationTherapeutic management of vitiligo
Minireview Submitted: 27.1.2018 Accepted: 14.3.2018 Conflict of interest None. DOI: 10.1111/ddg.13680 Therapeutic management of vitiligo Rachela Bleuel, Bernadette Eberlein Department Dermatology and Allergy
More informationClinical Policy Title: Platelet rich plasma
Clinical Policy Title: Platelet rich plasma Clinical Policy Number: 05.02.10 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: November 16, 2016 Next Review
More informationClinical Policy Title: Room humidifiers
Clinical Policy Title: Room humidifiers Clinical Policy Number: 17.02.05 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: November 16, 2016 Next Review Date:
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationClinical Policy Title: Discography
Clinical Policy Title: Discography Clinical Policy Number: 03.01.01 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2017 Next Review Date: October
More informationClinical Policy Title: Tactile breast imaging
Clinical Policy Title: Tactile breast imaging Clinical Policy Number: 05.01.07 Effective Date: February 1, 2018 Initial Review Date: November 16, 2017 Most Recent Review Date: January 11, 2018 Next Review
More informationBackground Head Quarter Promoter Holding Pattern Turnover
PhotoMedex, Inc INTRODUCTION Background PhotoMedex is a global skin health medical technology company, providing integrated disease management and aesthetic solutions through complementary laser and light-based
More informationMEDICAL POLICY SUBJECT: LIGHT AND LASER THERAPIES FOR DERMATOLOGIC CONDITIONS
MEDICAL POLICY SUBJECT: LIGHT AND LASER THERAPIES FOR PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationClinical Policy Title: Alopecia areata
Clinical Policy Title: Alopecia areata Clinical Policy Number: CCP.1134 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: August 1, 2018 Next Review Date:
More informationMaintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study
ORIGINAL ARTICLE Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study Marine Cavalié 1, Khaled Ezzedine 2, Eric Fontas 3, Henri Montaudié
More informationClinical Policy Title: Noninvasive tests for rejection surveillance after heart transplantation
Clinical Policy Title: Noninvasive tests for rejection surveillance after heart transplantation Clinical Policy Number: 04.01.04 Policy contains: Effective Date: January 1, 2016 Initial Review Date September
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationClinical Policy Title: Bone growth stimulators for non-healing fractures
Clinical Policy Title: Bone growth stimulators for non-healing fractures Clinical Policy Number: 14.02.03 Effective Date: January 1, 2015 Initial Review Date: July 16, 2014 Most Recent Review Date: March
More informationClinical Policy Title: Subtalar arthroereisis (implant)
Clinical Policy Title: Subtalar arthroereisis (implant) Clinical Policy Number: 14.03.05 Effective Date: April 1, 2017 Initial Review Date: August 17, 2016 Most Recent Review Date: September 21, 2017 Next
More informationClinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT)
Clinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT) Clinical Policy Number: 09.01.02 Effective Date: September 1, 2013 Initial Review Date: February 18, 2013 Most
More informationWhat s New in Alopecia Areata
AN UPDATE ON THE LAST 12 MONTHS What s New in Alopecia Areata PhD FRCPC Dermatologist Assistant Professor, University of Toronto Getting information out to Physicians Five new studies to discuss Can cholesterol
More informationالاكزيماتيد= Eczematid
1 / 7 2 / 7 Pityriasis Debate confusing of hypopigmentation characterized increasing surrounded differ hypomelanotic "progressive exists alba misnomer extensive a to observed term the applied term derived
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationClinical Policy Title: Seasonal influenza testing
Clinical Policy Title: Seasonal influenza testing Clinical Policy Number: 07.01.08 Effective Date: October 1, 2017 Initial Review Date: August 17, 2017 Most Recent Review Date: September 21, 2017 Next
More informationClinical Policy Title: Propel (drug eluting devices after sinus surgery)
Clinical Policy Title: Propel (drug eluting devices after sinus surgery) Clinical Policy Number: 10.03.07 Effective Date: July 1, 2017 Initial Review Date: May 19, 2017 Most Recent Review Date: June 22,
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationClinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT)
Clinical Policy Title: Immediate post-concussion assessment and cognitive testing (ImPACT) Clinical Policy Number: 09.01.02 Effective Date: September 1, 2013 Initial Review Date: February 18, 2013 Most
More informationClinical Policy Title: Home phototherapy for hyperbilirubinemia
Clinical Policy Title: Home phototherapy for hyperbilirubinemia Clinical Policy Number: 11.02.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17,
More informationClinical Policy Title: Bloodless heart transplant
Clinical Policy Title: Bloodless heart transplant Clinical Policy Number: 05.03.05 Effective Date: July 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next Review Date:
More information